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Sumoylationa b s t r a c t
RSUME (for RWD-domain-containing sumoylation enhancer), RWDD3 gene, was identified from a
pituitary tumor cell with increased tumorigenic and angiogenic potential, and has higher expression
in cerebellum, pituitary, heart, kidney, liver, pancreas, adrenal gland and prostate. RSUME is induced
by cellular stress like hypoxia and heat shock, and is increased in pituitary tumors, in gliomas and in
VHL tumors. Seven splicing forms have been described. Two of them correspond to non-coding RNAs
and the other five possess an RWD domain in the N-terminus and differ in their C-terminal end.
RSUME enhances SUMO conjugation by interacting with the SUMO conjugase Ubc9, increases
Ubc9 thioester formation and therefore favors sumoylation of specific targets. RSUME increases
IjB levels and stabilizes HIF-1a during hypoxia, leading to inhibition of NF-jB and increased HIF-
1 transcriptional activity. RSUME inhibits pVHL function, thus suppressing HIF-1 and 2a ubiquitina-
tion and degradation. Disruption of the RWD domain structure of RSUME indicated that this domain
is critical for RSUME action. The findings point to an important role of RSUME in the regulation and
stability of specific targets, which are key regulatory mediators in cancer and inflammation.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
RSUME (for RWD-domain-containing sumoylation enhancer),
also known as RWDD3, was cloned from the lactosomatotrophic
tumor cell line GH3 overexpressing the cytokine transducer
gp130 [1]. This cell line showed increased tumorigenic and angio-
genic potential when injected into nude mice [2], respect to a con-
trol GH3 stable clone for the empty vector. To date, seven human
RSUME mRNA splice variants have been described. Five of them
code for different RSUME isoforms and two variants correspond
to non-coding RNAs that suffer non-sense-mediated RNA decay, a
mechanism of degradation of mRNA with premature termination
codons [3,4]. The five isoforms have an RWD domain in the N-
terminus and are located in the cytoplasm and nucleus, in spite
of lacking a nuclear localization signal [1]. RSUME was found
highly expressed in various tissues such as pituitary, cerebellum,
heart, kidney, liver, pancreas, stomach, adrenal gland, prostate
and spleen. It has also been associated with the development of
neuropathic pain [5] and with other six genes in the molecular sig-
nature of the ganglionic eminence development [6]. Interestingly,it is upregulated by cellular stress such as hypoxia and heat shock
[1,7]. Moreover, RSUME expression is increased by hypoxia in
pituitary tumors [8], in the necrotic inner zone of gliomas [1]
and in VHL-dependent tumors [9], making RSUME an interesting
candidate for the understanding of those pathologies.
Posttranslational modification with small ubiquitin related
modifier (SUMO) has been characterized as a key regulatory
mechanism of protein function. SUMO belongs to the Ubiquitin
family and is comprised of four distinct proteins in humans
(SUMO-1, -2, -3, and -4). SUMO conjugation to the target protein
regulates its function and subcellular localization, thus sumoyla-
tion governs an increasing array of cellular pathways including
transport, transcription, cell cycle, DNA repair, replication and
mitochondrial dynamics [10–15]. This reversible posttranslational
modification is accomplished via an enzymatic cascade that con-
sists of different steps [11,16,17]. In an ATP-dependent step, the
E1-activating enzyme Aos1/Uba2 (SAE1/SAE2) forms a thioester
bond between its catalytic cysteine and the C-terminal carboxy
group of SUMO. In a following step, SUMO is transferred to the cat-
alytic cysteine of the E2-conjugating enzyme Ubc9. In the last part
of this cascade, an isopeptide bond is formed between SUMO and
the 3-amino group of a lysine side chain, usually with the partici-
pation of E3 ligases such as Protein Inhibitor of Activated STAT
(PIAS). Since it is a reversible process, specific isopeptidases,
members of the SENP family, eliminate the SUMO from the target
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key step of regulation. Extensive progress has been accomplished
in the identification of sumoylated proteins and the characteriza-
tion of the consequences of the modification of specific substrates.
RSUME enhances protein sumoylation of specific targets
through a direct interaction with the E2 SUMO conjugase Ubc9. A
proper folding of its RWD domain is essential for RSUME activity.
RSUME exerts this effect mainly in the formation of the Ubc9-
SUMO-1 thioester, and also acts in the transfer of SUMO-1 from
the thioester to a specific substrate [1]. Although RSUME exhibits
functional similarities to SUMO ligases, it has a more general func-
tion [1].
Recently, Alontaga et al. [18] analyzed the structure of RSUME
confirming, as we previously reported [1,3], that RWD is the only
well-structured domain in RSUME and participates in its binding
to Ubc9. Based on the crystal obtained they propose a complex
with two Ubc9 and one RWD molecule, although the NMR data
showed do not exclude other possible complexes. The absence of
action on global sumoylation in HEK293T cells without expression
of Ubc9 may be related to the critical dependence on the E2 for this
RSUME action. In line with our results [1], they confirmed that
RSUME stimulates Ubc9-SUMO thioester conjugate and added
the stimulation of the SAE2-SUMO thioester and SAE2-SUMO
isopeptide [18]. The fact that RSUME showed no effect on the
sumoylation of sp100 [18], points to the notion that RSUME only
acts on specific targets.
Several studies have shown that RSUME plays a key role in can-
cer and inflammation since it acts on specific targets related to that
processes such as Hypoxia-inducible factor (HIF)-1a, von Hippel–
Lindau protein (pVHL), IjB and glucocorticoid receptor (GR)
[1,3,7–9] thus pointing RSUME as an interesting regulator of these
pathways.2. RSUME in hypoxia and cancer
Tumors face two major metabolic challenges: how to support
enhanced cell growth and proliferation, and how to survive envi-
ronmental changes in nutrient and oxygen availability when tumor
growth exceeds the capacity of the existing blood vessels. Thus,
reduced oxygen availability (hypoxia) stimulates metabolic adap-
tation in cells to promote energy production and reduce ATP con-
sumption. This metabolic shift is synchronized by HIF-1, a
transcription factor complex activated by hypoxic stress [19–21].
Under normal oxygen tension, HIF-1a accumulation is suppressed
through prolyl hydroxylation (Pro402 and Pro564), leading to its
ubiquitination by pVHL, which is part of the ECV complex (Elon-
gins, Cullins and pVHL) and subsequent proteosomal degradation.
During hypoxia, prolyl hydroxylation of HIF-1a is reduced, HIF-
1a is not recognized by pVHL, causing HIF-1a protein stabilization,
translocation to the nucleus, association with the HIF-1b subunit,
and increasing HIF-1 transcriptional activity [22]. HIF-1 activity
triggers the upregulation of a number of genes involved in aerobic
glycolysis, including glucose transporters, glycolytic enzymes, and
LDH-A, angiogenesis (such as VEGF), erythropoiesis, vascular tone
and cell proliferation [22,23].
RSUME expression is induced by hypoxia and thus it might play
a role in the cell’s response to hypoxic stress [1]. Moreover, under
hypoxic conditions, RSUME overexpression increases HIF-1a pro-
tein levels [1]. As a functional readout of HIF-1a stabilization, dur-
ing hypoxia RSUME induces Vascular endothelial growth factor
(VEGF) promoter activity and mRNA and protein expression, fur-
ther validating the functional relevance of the interaction between
RSUME and HIF [1,8]. Deletion in the RSUME promoter of the con-
sensus sequence (RCGTG) reported to be critical for HIF-1 binding
[22] abolished RSUME induction during hypoxia [1]. Furthermore,downregulation of endogenous RSUME resulted in the inhibition of
endogenous HIF-1 a stabilization during hypoxia indicating an
interaction between RSUME and HIF-1a [1]. Interestingly, RSUME
sumoylates and physically interacts with pVHL in normoxia, and
negatively regulates the assembly of the complex between pVHL,
Elongins and Cullins (ECV), inhibiting HIF-1 and 2a ubiquitination
and degradation [9] (Fig. 1).
As mentioned, RSUME is expressed in pituitary tumors [1,8] and
gliomas [1,3], which will be further discussed below. The interplay
between copy number variation (CNV) and differential gene
expression may be able to shed light on molecular process under-
lying breast cancer and lead to the discovery of cancer-related
genes. In this sense, RSUME has been associated with the gene
expression signature of breast cancer patients, which display high
risk of recurrence and metastases [24]. These results might have a
predictive value since RSUME, as a part of this signature, could be
used as biomarker with prognostic function in breast cancer. What
is more, RSUME has been identified in a genome-wide association
study on 2204 breast cancer patients [25]. Its relevance in VHL
tumors is discussed below.
2.1. Pituitary and central nervous system tumors
Normal pituitary cells are under endocrine as well as auto-/
paracrine control of numerous growth factors, so any disturbance
in the expression and/or action of these components and their
receptors might commit to pituitary tumor development and pro-
gression. Indeed, alterations in the expression of cytokines/growth
factors and their receptors have been reported in pituitary tumors
[26,27].
Pituitary tumors represent the most common intracranial neo-
plasms causing serious morbidity through mass effects and exces-
sive or insufficient secretion of pituitary hormones. Radiological
and autopsy studies suggest a prevalence of 22.5% [28,29].
As in any solid tumor, neovascularization is essential for pitu-
itary adenoma progression, since the expanding tumor cell popula-
tion requires nutrients and oxygen [30,31]. Furthermore, the
anterior pituitary is one of the most densely vascularized mam-
malian organs due to the communication among hypothalamus,
pituitary, and target organs, which is mediated predominantly
through soluble substances transported within the bloodstream.
Neovascularization is induced by angiogenesis, a process by which
distinct tumor cell-derived soluble factors induce the sprouting of
new vessels and ingrowth into the developing tumor [32,33].
Hypoxia triggers neovascularization through HIF, which induces
the expression of different angiogenic factors such as VEGF-A,
bFGF, and PDGF [27,34]. In particular, VEGF-A, which also stimu-
lates pituitary tumor cell growth, is thought to play a key role in
pituitary tumor progression, as many reports show correlations
between VEGF-A and vessel density, adenoma type, size, and inva-
siveness [35]. In this context, RSUMEmay have a crucial role in this
process. As mentioned, RSUME was shown to stabilize HIF-1a dur-
ing hypoxia, thus inducing expression of angiogenic factors like
VEGF-A [1] to trigger the formation of new vessels and, ultimately,
to improve oxygen delivery under persistent hypoxic conditions. In
this line, Shan et al. demonstrated that RSUME mRNA is up-
regulated in pituitary adenomas and significantly correlated with
HIF-1a mRNA levels [8]. Hypoxia enhanced RSUME and HIF-1a
expression, induced translocation of this transcription factor to
the nuclei and stimulated VEGF-A production both in pituitary
tumor cell lines and primary human pituitary adenoma cell cul-
tures [8]. In addition, when RSUME expression was specifically
down-regulated, VEGF-A expression was strongly reduced [8,36].
By supporting pituitary tumor neovascularization, RSUME repre-
sents a new putative therapeutic target for the development of
new anti-angiogenic treatment for pituitary tumors [37].
Fig. 1. RSUME stabilizes HIF-a acting mainly on pVHL and as a consequence increasing the expression of its specific targets such as VEGF that contribute to vascularization
and cancer progression.
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characterized by extensive hypoxic areas and arise from neoplasti-
cally transformed neural stem or progenitor cells [38]. Due to the
fact that they include a variety of histologic types, most glioma
classifications have relied on the morphological similarities of the
tumor cells with non-neoplastic glial cells and as a consequence,
are classified as astrocytic, oligodendroglial, mixed oligo-
astrocytic, or ependymal tumors [38]. However, integrated geno-
mic studies and exome sequencing have demonstrated the exis-
tence of multiple distinct molecular subtypes within histological
classification [39] and this is fundamental for the clinical course
or response to therapy. To date, only three biomarkers have been
identified as potent prognostic factors in gliomas: codeletion of
chromosomes 1p/19q, O6-methylguanineDNA methyltransferase
(MGMT) promoter methylation, and mutations in isocitrate dehy-
drogenase (IDH) IDH1/2 genes [39,40].
RSUME was found to be expressed in glioma tumors. In those
tumors in which two clearly different regions could be identified,
Carbia-Nagashima et al. found RSUME protein expression in the
necrotic inner zone but not in the peripheral zone of the tumor
[1]. The mRNA and protein levels of RSUME isoforms differ in
human glioma samples; while the RSUME195 isoform (195
aminoacids) is expressed in all the tumors analyzed, the longest
variant (267 aminoacids) is expressed in most but not all of them
[3]. These results suggest non-redundant functions of these two
RSUME variants and a constitutive role of RSUME195 in the
gliomas.
The fact that RSUME is induced by hypoxia in tumors and con-
sidering that it is expressed in the necrotic zone of gliomas, under-
scores the importance of RSUME during hypoxia in tumorigenesis.
Likewise, NF-jB and HIF-1a have been proposed to interact in the
regulation of angiogenesis, since cells lacking HIF-1a show anincrease in NF-jB reporter activity important for the induction of
IL-8 in colon cancer cells [41]. Unravelling the diverse pathways
involved in angiogenesis and tumorigenesis in which sumoylation
and RSUME cooperate is fundamental to develop better combined
therapeutic strategies in the future.
2.2. VHL-dependent tumors
The VHL gene is involved in oxygen sensing under physiological
condition and its mutations predispose carriers to devastating
tumors [42]. pVHL loss-of-function mutations result in organ-
specific tumors, such as hemangioblastoma of the central nervous
system, renal clear-cell carcinoma (RCC) and pheochromocytoma
of the adrenal gland, untreatable with conventional chemothera-
pies [43–45]. The pVHL protein is best known as an E3 ubiquitin
ligase that targets HIF-a, but many diverse, non-canonical cellular
functions have also been assigned and are still unresolved.
The presence of these diverse but specific VHL tumor types of
different tissue origins is one of the intriguing facts about the
VHL gene [46]. pVHL is best known as the substrate- binding sub-
unit of a SCF (Skp1-Cdc53/Cul-1-F-box protein) type E3 ubiquitin
ligase containing, besides pVHL, Cullin-2, elongin B and C
and Rbx-1 [47,48]. The best-known degradation target of
VHL-containing E3 ligase is HIF-a in normal physiological
conditions [49,50].
By using a bioinformatic analysis in the cBioPortal for Cancer
Genomics we analyzed RCC samples from the Cancer Genome Atlas
Research Network and found that 4% of the tumors expressed high
levels of RSUME and these patients exhibited a decrease in the sur-
vival rate [9,51–53].
Since RSUME is expressed in tumor necrotic areas and in tissues
sensitive to VHL disease and given that VHL-dependent tumors
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underlying mechanisms that lead to tumorigenesis, we investi-
gated the action of RSUME on pVHL. Interestingly, RSUME stabi-
lizes HIF-a by inhibiting pVHL. We found that RSUME increases
pVHL sumoylation [9] in line with previous results showing that
RSUME is a sumoylation enhancer of specific substrates, that inter-
acts with pVHL, an interaction that is HIF-1a independent and that
inhibits pVHL binding to Elongin C and Elongin B [9]. In this way,
RSUME inhibits pVHL-dependent HIF-a ubiquitination (Fig. 1).
When analyzing human pVHL-deficient tumors, we obtained
compelling data showing that pheochromocytoma, hemangioblas-
toma and RCC-786-O cell line express high levels of RSUME [9]. In
this cell line, RSUME inhibits pVHL/HIF-2a interaction and acts
preventing HIF-2a ubiquitination [9]. It has been shown that short
hairpin RNA against RSUME (although its efficiency was not tested)
did not lead to a change in the level SUMO-modified HIF-2a in
hypoxic conditions [54]. In order to elucidate the contribution of
the direct regulation of pVHL function by RSUME in an in vivo
tumor model, we evaluated tumor formation and vascularization
in nude mice injected either with RCC-786-O cells or with stable
transfected clones with a short hairpin RNA for RSUME. The strik-
ing results revealed that the mice injected with clones in which
RSUME was silenced, showed a significant reduction of the tumor
size, lower HIF-2a and a consistent decrease in VEGF-A levels as
well as in vessel density [9]. These data shed light on the critical
role of RSUME on pVHL and thus, on ECV homeostasis and its
impact in VHL disease tumorigenesis.
3. RSUME in inflammation
An important characteristic of the inflammatory response is the
marked increase in cytokine production that activates the hypotha
lamic–pituitary–adrenal system, causing an increase of systemic
glucocorticoid (GC) levels. GCs have a central role in the interaction
between the neuroendocrine and the immune systems in order to
maintain homeostasis of the whole body, avoiding excessive
destruction and inflammation [55]. GCs inhibit cytokine gene
expression and act as immunosuppressive and anti-inflammatory
agents [55–57].
GCs are lipophilic molecules with the capability of diffusing
through the cell membrane and binding the GC receptor (GR),Fig. 2. RSUME stabilizes IjB and increases GR transcriptional activity thus increasing thewhich is a transcription factor capable of regulating either posi-
tively or negatively the expression of target genes [58–60]. Upon
interaction with GCs, the GR dissociates from the complex with
heat shock proteins (hsp), hsp-associated proteins, and immuno-
philins and translocates to the nucleus [58,59].
In the nucleus the GR binds as homodimer to specific palin-
dromic DNA consensus sequences, the glucocorticoid response ele-
ments (GREs) by transactivation [58]. The GR can also modulate
gene responses by protein–protein interaction, which is commonly
responsible for repression of transcription of target genes. This
mechanism is called transrepression and involves the physical
association between GR and other transcription factors, such as
activating protein-1 (AP-1), nuclear factor-jb (NF-jb), and signal
transducers and activators of transcription (STAT) family
members implicated in signaling of inflammatory and immunoreg-
ulatory responses [61–63]. GCs can inhibit inflammation by
abrogating the activity of NF-jB, which regulates the production
of proinflammatory cytokines and thus, GR activity is critical for
the anti-inflammatory response [60,64].
Transcriptional activity of steroid receptors and transcription
factors involved in immune and inflammatory responses may be
regulated by posttranslational modifications such as phosphoryla-
tion, acetylation, prenylation, and even by covalent attachment of
polypeptides, such as ubiquitin and SUMO [60]. As a result, GR reg-
ulation involves an adjustment in the inflammation process. In
some cases, SUMO and ubiquitin conjugation compete for the same
lysine residues on protein substrates; thus sumoylated proteins
can avoid ubiquitin-mediated degradation, this being the case of
the inhibitor of jb (Ijb) [65,66]. RSUME increases Ijb sumoylation
and stability. In addition, immunoprecipitation assays show a
direct interaction between RSUME and Ijb. Furthermore, RSUME
inhibits TNF-a-induced jB-LUC (Luciferase) reporter activity,
showing the functional consequence of Ijb increased stability
[1,3]. RSUME-enhanced sumoylation of Ijb leads to the inhibition
of NF-jb activity on two well-known inflammatory genes, IL-8
and cyclooxygenase-2 (Cox-2) and therefore may also favor anti-
inflammatory pathways [1] (Fig. 2).
The GR has three sumoylation sites: lysine 297 (K297) and K313
in the N-terminal domain (NTD) and K721 within the ligand-
binding domain [67,68]. Interestingly, Druker et al. demonstrated
that RSUME interacts with GR and increases its sumoylation, thusexpression of its specific targets that ultimately lead to the control of inflammation.
3334 V.G. Antico Arciuch et al. / FEBS Letters 589 (2015) 3330–3335regulating GR transcriptional activity and the expression of its
endogenous target genes, FKBP51 and S100P [7] (Fig. 2). RSUME
uncovers a positive role for the third sumoylation site, K721, on
GR-mediated transcription, demonstrating that GR sumoylation
acts positively in the presence of this sumoylation enhancer [7].
In line with these results, mutation of K721 and small interfering
RNA-mediated RSUME knockdown diminished GRIP1 coactivator
activity. Given that RSUME expression is induced under stress con-
ditions, it has a role in heat shock-induced GR sumoylation [7].
Sumoylation of the NTD sites mediates the negative effect of the
synergy control motifs of GR on promoters with closely spaced GR
binding sites. This third site could become relevant in a scenario of
increased RSUME expression, such as under cellular stress condi-
tions, in which RSUME can function as a molecular switch of the
negative to positive action of SUMO conjugation to the GR. Under-
standing the actions of RSUME on specific targets involved in
inflammatory responses provides further insight in the regulatory
network of immune-inflammatory signals.
4. Conclusions and perspectives
Since the cloning and characterization of RSUME, several stud-
ies have pointed out its role in the regulation of specific targets.
Considering that pVHL has a central role as a tumor suppressor
and possesses non-canonical functions, its fine regulation through
RSUME determines another important step in the regulation of HIF
targets such as VEGF, with an outcome in vascularization and ulti-
mately, to cancer progression. RSUME is also implicated in the
development of pancreatic neuroendocrine tumors and acts on
the tumor suppressor PTEN (U. Renner personal communication),
which is frequently lost in PanNETs. This action on PTEN reinforces
the role of RSUME on several specific targets related to cancer.
GRs have a pivotal action in the anti-inflammatory response
and the modulation of its activity by sumoylation, particularly,
an increase in its transcriptional activity by RSUME provides a
novel understanding of the inflammatory pathway. In accordance,
IjB stabilization by RSUME, that leads to a decrease in the
expression of NF-jB targets, also contributes to the promotion of
the anti-inflammatory response.
RSUME appears as an interesting player in the cross-talk of both
inflammatory and hypoxic-angiogenic factors, a hypothesis and
mechanism to be explored in the future.
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